PLYMOUTH, Minn., May 22, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that the CMS has established a unique billing code and payment for endoscopic balloon dilation to treat Eustachian tube dysfunction (ETD). The code, C9745, will become effective July 1, 2017 and will facilitate payment for the outpatient treatment of ETD using balloon dilation in hospitals and ambulatory surgery centers (ASC).
“We are pleased by CMS’s decision to establish payment for endoscopic balloon dilation to treat ETD,” said Robert White, President and Chief Executive Officer of Entellus Medical. “The new payment code is associated with a national average payment of $4,130 in the hospital outpatient department, a payment that is consistent with those made for balloon dilations of the various sinus cavities in patients with chronic and recurring acute sinusitis. With the creation of a unique code and payment that is intended to cover the cost of the device and procedure, CMS removed one of the biggest obstacles to providers who seek to bring this innovative new treatment to their patients.”
C codes are unique temporary pricing codes that were initially established by CMS for the Hospital Outpatient Prospective Payment System (HOPPS) to promote the adoption of new medical technology that otherwise had no codes to facilitate payment. These payment codes are typically available for two to three years and Entellus believes, based on long-standing CMS policy, that billing code and payment for endoscopic balloon dilation to treat ETD will be effective through the end of 2019. C codes are used on Medicare HOPPS claims but may also be recognized on claims from other providers or by other payment systems.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of patients. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus Medical platform of products provides effective and easy-to-use solutions intended to help simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]


Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal
ASML’s EUV Monopoly Powers the Global AI Chip Boom
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
Google Halts UK YouTube TV Measurement Service After Legal Action
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 



